We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy

Unwrap our new Directory

RAS G12D

.Clinical

Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...

By cGxPwire Editor
July 3, 2026

Recent Posts

01

.Clinical

Newron Reports FDA Progress on Evenamide Phase 3 ENIGMA-TRS 2 Trial
July 3, 2026
02

.Clinical

NKGen Biotech to Highlight Troculeucel Alzheimer’s Program at BIOCHINA Forum
July 3, 2026
03

.Clinical

Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer
July 3, 2026
04

.Clinical

Multitude Therapeutics Reports Positive AMT-676 Phase I Data
July 3, 2026
05

Bio-Pharma

Myriad Genetics Prolaris Study Validates Prostate Risk Test
July 3, 2026